Search Results

Keywords: sativex

New Zealand eases prescription requirement for cannabis-based medicine Sativex

Doctors in New Zealand no longer require Ministry of Health approval to prescribe Sativex, according to a new notice published in the country’s official Gazette – a move that could facilitate access to the pharmaceutical-grade, cannabis-based product. Any move to reduce bureaucratic-level processing of cannabinoid prescriptions is seen as a boon for patient access as well […]

Read More

Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement

United Kingdom-based GW Pharmaceuticals showed revenue of $39.2 million for the quarter ended March 31, 2019, compared with $3 million in the same period a year ago. The maker of cannabis-derived medications, including Sativex and Epidiolex, recorded a net loss for the quarter of $50.1 million compared with a year-ago net loss of $69.5 million. […]

Read More

First prescriptions of high-THC products imminent in Peru

Khiron Life Sciences – a Toronto-based company with its main operations in Colombia – announced Thursday that it completed the first export from Colombia of high-THC medical cannabis products. They were imported into Peru. The first prescriptions of the products in Peru are expected to be filled in December through a partnership with pharmacy chain Farmacia […]

Read More

Brazil postpones evaluation of CBD formulation for medical coverage

A government evaluation to include a specific CBD formulation in Brazil’s Public Health System (SUS) has been postponed. The National Committee for Health Technology Incorporation (Conitec), a government agency, had been scheduled to take up the issue this week. Instead, the evaluation will now occur in early 2021. A decision by Conitec to include the […]

Read More

Epidiolex maker GW Pharma reports record quarterly revenue of $137 million

United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by U.S. sales of its cannabidiol medicine Epidiolex. GW’s total revenue for the third quarter reached $137.1 million, about 16% more than the previous quarter’s $121.3 million. Epidiolex sales in the United States accounted for 87% of the company’s overall […]

Read More

More medical cannabis products available in Peruvian pharmacies

The first finished, registered cannabis medicine became available to patients in Peruvian pharmacies this week, Marijuana Business Daily has learned. The product, Epifractan, is manufactured in Uruguay by Ramm Pharma and imported into Peru by Cann Farm, holder of the registry with the Peruvian General Directorate of Medicines, Supplies and Drugs (DIGEMID). Magistral preparations first […]

Read More

Danish medical cannabis market sees positive quarter

Denmark’s medical cannabis pilot program notched another positive quarter, but the number of unique consumers remains well below the trial’s peak of a year ago. The Danish market’s struggles demonstrate how businesses need to factor market ebbs and flows into their projections rather than counting on consistent, perpetual growth. In the second quarter of 2020, the […]

Read More

Australia approves record number of medical cannabis patients

Australia’s medical cannabis market continues to grow. In September, more than 6,000 patients were approved for medical marijuana treatment through the country’s Special Access Scheme (SAS) Category B pathway. That’s the highest monthly gain since 2016 – when the majority of approvals started occurring. Roughly 67,000 applications for unapproved medicinal cannabis products have been granted […]

Read More

New CBD product available under prescription in Peru

A new medical cannabis product is available in Peru, another sign the market is moving in the right direction in terms of business opportunities. Toronto-headquartered Khiron Life Sciences, a company with its main operations in Colombia, said it became the “first company to sell and fill medical cannabis prescriptions through private pharmacies in Peru.” Khiron’s […]

Read More